<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04360343</url>
  </required_header>
  <id_info>
    <org_study_id>LG-SGCL003</org_study_id>
    <nct_id>NCT04360343</nct_id>
  </id_info>
  <brief_title>Compare the Pharmacokinetics, Pharmacodynamics and Safety/Tolerability of LC51-0255 Film-coated Tablet (SG85) With LC51-0255 Uncoated Tablet (SG82) in Healthy Subjects</brief_title>
  <official_title>A Randomized, Open-label, Single Dose, 2-period, 2-sequence, 2-treatment, Crossover Study to Compare the Pharmacokinetics, Pharmacodynamics and Safety/Tolerability of LC51-0255 Film-coated Tablet (SG85) With LC51-0255 Uncoated Tablet (SG82) in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Chem</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Chem</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the pharmacokinetics, pharmacodynamics and safety/tolerability of LC51-0255&#xD;
      film-coated tablet (SG85) with LC51-0255 uncoated tablet (SG82) in healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Actual">December 1, 2020</completion_date>
  <primary_completion_date type="Actual">October 1, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic Outcome Measures</measure>
    <time_frame>baseline,during the procedure</time_frame>
    <description>Peak Plasma Concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Outcome Measures</measure>
    <time_frame>baseline,during the procedure</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>LC51-0255 film-coated tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: LC51-0255</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LC51-0255 uncoated tablet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: LC51-0255</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Film-coated tablet</intervention_name>
    <description>uncoated tablet</description>
    <arm_group_label>LC51-0255 film-coated tablet</arm_group_label>
    <arm_group_label>LC51-0255 uncoated tablet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy males and females between the age of 19 and 45 at the screening visit&#xD;
&#xD;
          2. Subjects with the Body Mass Index (BMI) measurement results between 18.0 kg/m2 and&#xD;
             27.0 kg/m2 at the screening visit&#xD;
&#xD;
          3. Subjects who were confirmed to be healthy based on the medical history&#xD;
&#xD;
          4. Subjects who make a voluntary decision to participate in this clinical study and&#xD;
             provide the informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with a clinically significant disease or history in liver, kidney,&#xD;
             gastrointestinal system, respiratory system, musculoskeletal system, endocrine system,&#xD;
             neuropsychiatric system, hemato-oncology system or cardiovascular system&#xD;
&#xD;
          2. Subjects with a disease (e.g., Crohn's disease, etc.) or history of surgery (except&#xD;
             for simple appendectomy and herniotomy) in gastrointestinal system which may affect&#xD;
             the absorption of the investigational product&#xD;
&#xD;
          3. Subjects with a history of clinically significant disease or suspicious sign/symptom&#xD;
             of ophthalmologic disease including uveitis and retinitis at the screening visit&#xD;
&#xD;
          4. Subjects who had donated whole blood within 2 months, component blood within 1 month,&#xD;
             or received transfusion within 1 month prior to the first administration day&#xD;
&#xD;
          5. Subjects who had taken an inducer or inhibitor of drug metabolism such as barbiturates&#xD;
             etc. within 1 month prior to the first administration day&#xD;
&#xD;
          6. Subjects who had eaten grapefruit/caffeine-containing food within 3 days prior to the&#xD;
             first hospitalization or subjects who could not stop taking food containing grapefruit&#xD;
             or caffeine from 3 days prior to hospitalization to the discharge day&#xD;
&#xD;
          7. Subjects who had taken any prescription drug or herbal medicine within 2 weeks or any&#xD;
             over the counter (OTC) drug within 1 week prior to the first administration day&#xD;
             (however, subjects fulfilling other conditions could participate in the study at the&#xD;
             investigator's discretion)&#xD;
&#xD;
          8. Subjects who taking excessive caffeine or alcohol or heavy smoker (caffeine &gt; 5&#xD;
             units/day, alcohol &gt; 21 units/week (1 unit = 10 mL as pure alcohol), smoking &gt; 10&#xD;
             cigarettes/day)&#xD;
&#xD;
          9. Subjects who had a history of tuberculosis (TB) infection or a positive result in the&#xD;
             Quantiferon TB-Gold test and the chest X-ray in the screening tests&#xD;
&#xD;
         10. Subjects who unable to take the food provided by the study institution&#xD;
&#xD;
         11. Subjects who with a positive result in the serology test (hepatitis B test, human&#xD;
             immunodeficiency virus (HIV) test, hepatitis C test, syphilis test)&#xD;
&#xD;
         12. Other cases that the investigator consider unsuitable as the subject&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seoul National University College of Medicine and Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>April 6, 2020</study_first_submitted>
  <study_first_submitted_qc>April 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2020</study_first_posted>
  <last_update_submitted>January 20, 2021</last_update_submitted>
  <last_update_submitted_qc>January 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

